As of May 27, 2025, Avidity Biosciences Inc (RNA) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Avidity Biosciences Inc's Forward P/E to Peers
To better understand Avidity Biosciences Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Avidity Biosciences Inc (RNA) | - |
| MeiraGTx Holdings PLC (MGTX) | 206.31 |
| Theratechnologies Inc (TH.TO) | 77.87 |
| Vertex Pharmaceuticals Inc (VRTX) | 23.87 |
| MannKind Corp (MNKD) | 22.44 |
| Regeneron Pharmaceuticals Inc (REGN) | 16.17 |
Compared to its competitors, Avidity Biosciences Inc's Forward P/E is difficult to compare due to insufficient data.